Publications

Randomised Phase Ii Study Evaluating, as First-Line Chemotherapy, Single-Agent Oral Vinorelbine Administered with Two Different Schedules in Patients with Hormone Receptor Positive, Her2-Negative Advanced Breast Cancer (Tempobreast-1 Trial)

AuthID
P-00K-GCX

Author(s)

De la Haba, J

Cazzaniga, M

Freyer, G

Costa, L

Petru, E

Bartsch, R

Staroslawska, E

de Almeida, C

Villanova, G

Cardoso, F

Document Type

Abstract

Year published

2016

Published

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 76, Issue: 4 Supplement, Pages: OT3-02-04-OT3-02-04 (2)

Conference

38Th Annual Ctrc-Aacr San Antonio Breast Cancer Symposium, Date: DEC 08-12, 2015, Location: San Antonio, TX, Sponsors: Canc Therapy Res Ctr, Amer Assoc Canc Res

Indexing

Wos^®

Crossref^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1158/1538-7445.sabcs15-ot3-02-04

Wos: WOS:000375622401175

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Randomised Phase Ii Study Evaluating, as First-Line Chemotherapy, Single-Agent Oral Vinorelbine Administered with Two Different Schedules in Patients with Hormone Receptor Positive, Her2-Negative Advanced Breast Cancer (Tempobreast-1 Trial)

Useful Links

Get Help

Federated Authentication (Click on the image)

Randomised Phase Ii Study Evaluating, as First-Line Chemotherapy, Single-Agent Oral Vinorelbine Administered with Two Different Schedules in Patients with Hormone Receptor Positive, Her2-Negative Advanced Breast Cancer (Tempobreast-1 Trial)

Useful Links

Get Help